That’s a wrap on #AUA25 for Team IP!

See you in Washington DC for #AUA26! 🇺🇸

Update of #IP9ATLAS presented by Archana Gopalakrishnan at #AUA25 🇺🇸

This pivotal RCT will evaluate MRI-based surveillance for patients with GG1-2 cancer starting active surveillance

Recruitment is open across the UK!

Update of #IP7PACIFIC presented by @ajwlight.bsky.social at #AUA25 🇺🇸

This will be the first trial to provide definitive evidence comparing bpMRI vs mpMRI, alongside fusion vs cognitive biopsy

>1200 patients recruited across the UK - watch this space

In further #RAPID data, Chase Ng shows that patients discharged from a pre-biopsy MRI pathway with ASAP or HGPIN do not have a greater risk of subsequent csPCa or treatment than patients discharged without

#AUA25 🇺🇸

Pilot results from #IP2ATLANTA on novel cytoreductive treatments to the prostate & mets in de novo mHSPC presented by @londonprostate1.bsky.social #AUA25 🇺🇸

Take home - these treatments are safe and justified

Recruitment for the main trial has completed - PFS endpoint to be reported 2027

Building on our #IP8FLUORESCE study is #IB1LaserCOMPLETE - using ex vivo fluoresce confocal microscopy to establish muscle status in TURBT, presented by Archana Gopalakrishnan

Recruitment is under way - watch this space for results soon! #AUA25 🇺🇸

@ajwlight.bsky.social presents preliminary validation data on the #TARGET scoring system - good specificity and NPV for detecting GG2+ in-field disease

Watch this space for our definitive multi centre validation study! #AUA25 🇺🇸

Excellent podium presentation by our resident Chase Ng on >1200 patients in #RAPID discharged with negative MRI or biopsy

Only 1 in 12 developed csPCa & 1 in 20 needed cancer treatment by 5 years

More evidence of the oncological efficacy of pre-biopsy MRI! #AUA25 🇺🇸

5yr outcomes following Rezum for >80mL prostates presented by @ajwlight.bsky.social (on behalf of Yan Leung) #AUA25 🇺🇸

Take home message - 3 of 4 patients were free of retreatment by 5 years

Powerful messages from @londonprostate1.bsky.social in the focal therapy plenary crossfire debate

Most intermediate risk cases are suitable, focal therapy is very effective, and the functional outcomes are superior. Surgeon training is crucial!

#AUA25 🇺🇸

Greetings from Las Vegas! #AUA25 🇺🇸

New publication alert! 🚨

A clinician survey on the current practices within the prostate cancer diagnostic pathway in the United Kingdom - Uma Walters et al (Journal of Clinical Urology)

🔗 doi.org/10.1177/2051...

Imperial Prostate Masterclass

👀🤏🏽 We're squeezing a few more in! 🚨Registrations for the Imperial Prostate & Focal Therapy Society Masterclass 2025 close at midnight on Sunday 06/04 - secure your spot now before it's too late! ✨

View the agenda 🔗 www.imperialprostatemasterclass.org

#IPFTSmasterclass25

Description Please note that job descriptions are not exhaustive, and you may be asked to take on additional duties that align with the key responsibilities ment...

📢 Join us at @IP_London

We are recruiting a Clinical Research Fellow to join the #IP13AVIDITY team: RCT evaluating the role of PSMA PET/CT in directing treatment in patients w/ high-risk PCa (closing 15/04)

🔗 www.imperial.ac.uk/jobs/search-...

@londonprostate1.bsky.social @connorurol.bsky.social

I treat prostate cancer every day – now I'm launching a study that could transform screening and save lives The debate on screening for prostate cancer has been raging for over two decades.

💬 #TRANSFORM will look at new ways of screening to reduce false positives, reduce biopsy rates and reduce diagnosing low risk cancers whilst finding more high risk cancers that need treating.

@londonprostate1.bsky.social @prostatecanceruk.bsky.social @nihr.bsky.social

www.lbc.co.uk/opinion/view...

With presentations from 4 IP trials and multiple other projects, it’s been a fantastic #EAU25 for Imperial Prostate 🇪🇸

See you next year in London for #EAU26! 🇬🇧

#IP2ATLANTA RCT pilot result #EAU25 🇪🇸

🔬 9 in 10 patients have a viable prostate tumour despite ADT+ARTA/Doce

🚦Early signal in prostate cancer mortality for cytoreductive arms

📈 Surgery, radiotherapy or ablation + SABR safe - Recruited (n=433) PFS exp.2027!

@connorurol.bsky.social

Building on this morning’s #NeuroSAFE data, @nikhilmayor.bsky.social presents late-breaking results from #IP8FLUORESCE, assessing the diagnostic accuracy of FCM for detecting positive margins intra-op

Feasible, quick and good sensitivity and specificity for detecting margins ≥3mm!

#EAU25 🇪🇸

Mr Chase Ng presents 5-year follow-up data for patients discharged with negative MRI/biopsy from our #RAPID pathway #EAU25 🇪🇸

1 in 12 were subsequently diagnosed with GG2+ cancer and 1 in 20 needed treatment - this further highlights the efficacy of MRI-based diagnostics!

It’s a big last day at #EAU25 for our team! 🇪🇸

@connorurol.bsky.social - 2x #IP2ATLANTA pilot study results (12:00)

Mr Chase Ng - #RAPID 5-yr follow-up for negative biopsy patients (12:05)

Mr Nikhil Mayor - #IP8FLUORESCE late breaking results (12:15)

Lastly for Imperial Prostate today @ #EAU25 🇪🇸 is Ms Deepika Reddy in the new technologies & focal therapy in localised PCa session

Traditional risk classification strategies developed for radical treatment are not transferrable to focal therapy outcomes. Risk models are in development!

Excellent presentation by Miss Yan Leung on 5-year outcomes after Rezum in >80mL prostates #EAU25 🇪🇸

75% retreatment-free at 5 years and the majority satisfied with their treatment!

And now @londonprostate1.bsky.social presents an update on the #TRANSFORM randomised prostate cancer screening study in the plenary session - recruitment starting later this year to answer some of the biggest questions in screening 📝📈 #EAU25

👀 @IP_London @ #EAU25 today!

Real world experience of Rezūm therapy (≥ 80g) - retreatment rates at 5 years follow up - Miss Yan Leung
📍Green Area EGPT1
⏱️ 15:30

Outcomes of focal HIFU for localised PCa determined by modern risk stratification strategies - Ms Deepika Reddy
📍Green Area Rm3
⏱️ 17:15

📣 Join Clinical Lecturer Mr Martin Connor as he presents the first Imperial Prostate randomised controlled trial - #IP2ATLANTA internal pilot results are out!

Live on Monday 12:00 ⏱️ #EAU25 🇪🇸

#CytoreductiveSurgery #SABR #Ablation @connorurol.bsky.social @londonprostate1.bsky.social

📣 Join Clinical Lecturer Mr Martin Connor as he presents the first Imperial Prostate randomised controlled trial - #IP2ATLANTA internal pilot results are out!

Live on Monday 12:00 ⏱️ #EAU25 🇪🇸

#CytoreductiveSurgery #SABR #Ablation @connorurol.bsky.social @londonprostate1.bsky.social

Is bpMRI non-inferior to mpMRI? Is image-fusion biopsy superior to cognitive biopsy?

@nikhilmayor.bsky.social gives an update on the #IP7PACIFIC trial with >1,000 patients recruited so far #EAU25 🇪🇸

Next up: PhD Fellow @ajwlight.bsky.social presents an update from the multicentre blinded #IP8FLUORESCE study evaluating #ConfocalMicroscopy for margin status in #RadicalProstatectomy - recruitment complete and results out on Monday 24/03 at #EAU25 🇪🇸

Next is Dr Archana Gopalakrishnan discussing the #IP9ATLAS trial

For active surveillance, is regular MRI superior to standard care for detecting progression? Recruitment is open and the trial will randomise 1263 patients in 30 centres. Watch this space! #EAU25 🇪🇸

Is bpMRI non-inferior to mpMRI? Is image-fusion biopsy superior to cognitive biopsy?

@nikhilmayor.bsky.social gives an update on the #IP7PACIFIC trial with >1,000 patients recruited so far #EAU25 🇪🇸